Card image cap
Sentynl Therapeutics buys global rights of fosdenopterin

Sentynl Therapeutics, a US biopharmaceutical subsidiary of Zydus Lifesciences (formerly Cadila Healthcare), has acquired the global rights of the new drug, fosdenopterin, indicated for reducing the risk of mortality in patients with molybdenum cofactor deficiency (MoCD), The drug, branded as NULIBRY, was developed by BridgeBio Pharma, Inc., which focuses on genetic diseases and cancers.  MoCD is a type A, an ultra-rare, life-threatening paediatric genetic disorder.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment